A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms BATTLE
  • Most Recent Events

    • 26 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 10 Aug 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov
    • 16 Sep 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top